Cost-effectiveness of trastuzumab: In the treatment of early stages breast cancer patients, in Portugal;Custo-efectividade de trastuzumab: No tratamento de doentes com cancro da mama em estádios iniciais em Portugal

Acta Medica Portuguesa

Volumn 23, Issue 3, 2010, Pages 475-482

  Macedo, Ana ^a   Monteiro, Isabel ^b   Andrade, Sofia ^a   Cirrincione, A ^c   Ray, J ^c  

^a KeyPoint Consultoria Científica Lda ^*  (Portugal)

^b Roche Farmacêutica Química Lda   (Portugal)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MORBIDITY; PORTUGAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; NEOPLASM STAGING; PORTUGAL;

EID: 77958518026     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. GERVÁSIO H: Nova terapêutica para o carcinoma da mama reduz em 17% o risco de morte. Anamnesis 2006;15(156):14-6
2. th May 2007]
3. th May 2007].
4. Herceptin Cost-Effectiveness Model For Early Breast Cancer: User Guide. Version 1.0. June 2006.
5. PICCART-GEBHART MJ et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM 2005;353:1659-72
6. WARDLEY et al: 31st ESMO Congress. Istambul 2006
7. BELL et al: 31st ESMO Congress. Istambul 2006
8. TENGS TO, WALLACE A: One thousand health-related quality-of-life estimates. Med Care 2000;38(6):583-637
9. Diário da República: Portaria no 110-A/2007, I Série no.16 de 23 de Janeiro de 2007
10. Ministério do Trabalho e Segurança Social: Boletim Estatístico do Gabinete de Estratégia e Planeamento - Abril 2007
11. In: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS-USO- HUMANO/AVALIACAO-ECONOMICA-E-COMPARTICIPACAO/MEDICAMENTOS-USO-HOSPITAL/ DL-N-195-2006-3